

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol						bol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
ZASLOFF MICHAEL A					Amphastar Pharmaceuticals, Inc. [AMPH]							_X_ Director 10% Owner				
(Last)	(First	t) (Mic	ddle)	3.	Date	of Ear	liest Trans	sactio	on (MM	/DD/YYY	Y)	Officer (giv	e title below) Oth	er (specify b	pelow)
C/O AMPHASTAR PHARMACEUTICALS, INC., 11570						5/16/2022										
6TH STREE	CT (Stre	eet)		4	If Ar	nendm	ent Date (Orig	inal Fil	ed (MM/I	DD/YYYY)	6. Individual o	or Joint/Gi	roup Filing	Check Appl	icable Line)
RANCHO C	CUCAMC						,	8		(,	X Form filed by	y One Repor			,
			Table I	- Non-De	erivat	ive Sec	curities A	cqui	red, Di	isposed	of, or Ben	eficially Owne	d			
1. Title of Security (Instr. 3)			2. 1	Trans. Date	te 2A. Deemed Execution Date, if any		3. Trans. Co (Instr. 8)	de	4. Securities Acquin Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)				7. Nature of Indirect Beneficial Ownership (Instr. 4)
							Code	V	Amount	(Ď)	Price				4)	
Common Stock 5/16/2022 Common Stock 5/16/2022							M S		10291 10291	A D	\$17.11 \$35.6136 (1)	57497 47206			D D	
Common Stock	Tab	ole II - Deri			Ben-	eficiall		(e.g.		! !	ļ	options, conver		rities)		
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Trans. Date	3A. Deem Execution Date, if an		e Deriva Acquir Dispos		ber of ive Securities ed (A) or ed of (D) , 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Securities U Derivative (Instr. 3 and	Security	Derivative Security	9. Number of derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	V	(A)	(D)	Dat Exc	te ercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	or Indirect	
Stock Option (right to buy)	\$17.11	5/16/2022		M			10291		(2)	6/8/2022	Common Stock	10291	\$0	0	D	

Explanation of Responses:

- (1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.591 to \$35.80, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- (2) Shares subject to the option are fully vested and immediately exercisable.

Reporting Owners

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
ZASLOFF MICHAEL A							
C/O AMPHASTAR PHARMACEUTICALS, INC.	v						
11570 6TH STREET	Λ						
RANCHO CUCAMONGA, CA 91730							

Signatures

/s/ Eva Wen, by power of attorney 5/17/2022

**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.